Literature DB >> 2600782

Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.

B S Chakraborty1, K K Midha, G McKay, E M Hawes, J W Hubbard, E D Korchinski, M G Choc, W T Robinson.   

Abstract

Dose proportionality in some pharmacokinetic parameters for thioridazine and its two active metabolites (mesoridazine and sulforidazine) was investigated in 11 healthy human subjects following oral administration of three single doses (25, 50, and 100 mg) of thioridazine hydrochloride separated in each case by an interval of two weeks. Also, after a further two weeks, another 100-mg dose of thioridazine (divided as 5 mg every 0.5 h) was administered to all the volunteers to investigate the effect of a slow rate of dosage input on the pharmacokinetic parameters of this drug. An HPLC method was used to measure concentrations of thioridazine, mesoridazine, and sulforidazine in plasma samples collected up to 72 h following each dose. Dose proportionality for the three single doses of thioridazine was observed for all three analytes in the area under the plasma concentration versus time curves (AUC infinity 0 or AUCt0) and the maximum plasma concentration (Cmax) in that the relationships between the dose and these parameters were each describable by an equation for a straight line (r2 greater than or equal to 0.8). However, the mean apparent distribution and elimination rate constants for thioridazine and mesoridazine and the mean apparent oral clearance for thioridazine decreased significantly with increasing dose. This suggests nonlinear trends in the elimination kinetics at high doses of thioridazine. When a 100-mg divided oral dose of thioridazine was administered, no statistically significant differences between single and divided doses were observed in the mean AUC infinity 0 or AUCt0 for thioridazine or sulforidazine. A significant decrease in the mean AUC infinity 0 or AUCt0 was observed for mesoridazine after the administration of the divided dose.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2600782     DOI: 10.1002/jps.2600781003

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors:  Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

2.  Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.

Authors:  Noton K Dutta; Michael L Pinn; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

3.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 4.  Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Authors:  K K Midha; J W Hubbard; S R Marder; B D Marshall; T Van Putten
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

5.  Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis.

Authors:  Noton K Dutta; Michael L Pinn; Ming Zhao; Michelle A Rudek; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2013-03-05       Impact factor: 5.790

Review 6.  Pharmacokinetic optimisation of the treatment of psychosis.

Authors:  A E Balant-Gorgia; L P Balant; A Andreoli
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

7.  Pediatric thioridazine poisoning as a result of a pharmacy compounding error.

Authors:  Zenichiro Kato; Mitsuhiro Nakamura; Yuka Yamagishi; Takahide Teramoto; Naomi Kondo
Journal:  Pediatr Rep       Date:  2009-06-08

8.  Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.

Authors:  Conor Mc Guire; Lynn Elton; Peter Wieghofer; Jens Staal; Sofie Voet; Annelies Demeyer; Daniel Nagel; Daniel Krappmann; Marco Prinz; Rudi Beyaert; Geert van Loo
Journal:  J Neuroinflammation       Date:  2014-07-21       Impact factor: 8.322

9.  NOX4-mediated ROS production induces apoptotic cell death via down-regulation of c-FLIP and Mcl-1 expression in combined treatment with thioridazine and curcumin.

Authors:  Seung Un Seo; Tae Hwan Kim; Dong Eun Kim; Kyoung-Jin Min; Taeg Kyu Kwon
Journal:  Redox Biol       Date:  2017-08-09       Impact factor: 11.799

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.